PF-07284892,lorlatinib,binimetinib,cetuximab,encorafenib
Pfizer,ono pharma,pierre fabre,eli lilly
['nsclc', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'sclc', 'lcsm,(-blcsm)']
quite an interesting work by group. shp2 does not work by itself, but it seems to restore efficacy of tkis in heavily pretreated patients, including alk+ nsclc and braf v600e mutant crc. #asco23 #lcsm 
Husband, Father.
Medical Oncologist and Researcher focused in Thoracic Oncology.
Views are my own.